Amorepacific Corporation

Samsung Electronics Co., Ltd.

Pacific Corporation

Jin Kyu Choi

Kyung Min Lim

Song Seok Shin

Jin Kwan Kim

Yeon Su Jeong

Sun-Young Kim

Ki-Wha Lee

Young-Ho Park

Byoung Young Woo

Hyun Ju Koh

Yung Hyup Joo

Young-Ger Suh

Uh Taek Oh

Joo Hyun Moh

Cheol Woo Kim

Hyeung-Geun Park

Hee-Doo Kim

Young Ho Park

Dae Bang Seo

Seung Kap Lee

Hyun Jung Shin

Jin Su Park

Jeongho Lee

Jin Woo Park

Joo-Hyun Moh

Byung Gyu Kim

Shin Chung

Joon Ho Bae

Jung Bum Yi

Min-Soo Noh

Yeonjoon Kim

Chang Hoon Lee

Hyun-Ju Koh

Seol Rin Park

Jun-Yong Ha

Sung-Il Kim

Jeong Il Park

Jin Young Park

Sang Jun Lee

Jun Young Lee

Hyeong Joon Seo

Kook Jeong Seo

Jeong Hoon Kang

Mi Na Jang

Ji Hoon Choi

In Ju Lee

Jin Yong Jang

Hyuk Hwan Kim

Dong Hyun Kim

Young Ho Kim

Yong Deog Hong

Miyoung Park

Eun Seok Hong

Phil Soo Chang

Jee Woo Lee

Hyeung Geun Park

Dong Lyoul Shin

Hee Doo Kim

Young Ger Suh

Il Hong Bae

Gil Yoon Kim

Valery Krasnoslobodtsev

Kyoung Hee Byoun

Ji Hye Jang

Mi Young Park

Seung Jin Yang

Jung Sun Hwang

Kyung Rae Cho

Sun Young Kim

Yong-Sil Lee

Chong Hyon Ryu

Young Hoon Choi

Yang Hui Park

Sung-II Kim

Min Kyoung Kwon

Sung Il Kim

Kyoung Min Lim

Jun Yong Ha

Chun Mok Chung

Young Joo Byun

Young Im Oh

Yong Sil Lee

Ok Hui Park

Sa-Yong Hong

Joo Hyun Kim

Seon-Hwa Kang

Seon Hwa Kang

Jee-Suk Kim

Funan Li

Jeong Hoon Yoon

Ji Young Kim

Jae-Young Choi

Shin Shinchang Missionhill Chung

Song Seok Sk Apt 102-2003 Shin

Kyoung Min Byeokjeoggol Lim

Byoung Young Chamsolmaeul World Meridian Woo

Joo-Hyun Amorepacific Moh

The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.

Composition for maintaining efficacy of filler

A cache and a method for performing data copying are provided. The cache includes a copy logic and be connected to a processor through a first bus and to a memory controller through a second bus, which is different from the first bus. Moreover, the copy logic may perform data copying through the second bus based on a data copy command received from the processor.

Method and apparatus for copying data using cache

Disclosed is a nozzle device and a minimally invasive injection device, and the nozzle device for a minimally invasive injection device according to an exemplary embodiment includes an outlet to generate a microjet of a liquid, and an injection part of a micro-scale size connected to the outlet and adapted to be inserted into a skin tissue to a preset depth.

Nozzle device and minimally invasive injection device comprising same

The present invention relates to a composition for maintaining efficacy of a filler for a long period of time by containing collagen as an active ingredient. The composition according to the present invention is useful since the composition can promote the synthesis of hyaluronic acid and inhibit activity of hyaluronidase, thereby maintaining the efficacy of a hyaluronic acid filler for a longer period of time. Therefore, even with less number of times of filler injection, the efficacy of the filler can be maintained and skin irritation can be also reduced.

Composition for maintaining effect of filler

Disclosed is a novel compound acting as a cannabinoid receptor 1 inhibitor, the compound being a pyrazolo[1,5-a]pyrimidine derivative, a prodrug thereof, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof. The novel compound or the like is useful for preventing or treating diseases mediated by the cannabinoid receptor-1.

Compound acting as a cannabinoid receptor-1 inhibitor

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same

This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same

The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

Thiourea derivatives and the pharmaceutical compositions containing the same

2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-&#x3b1; or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-&#x3b1; or PDE4.

2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-&#x3b1;

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

A variable capacity rotary compressor capable of reducing collision noise of a vane with a roller. The variable capacity rotary compressor includes a vane controller controlling the operation of a vane in order to vary compression capacity. The vane controller includes a control valve that switches a fluid channel so as to selectively apply discharge pressure and intake pressure to the vane guide slot, a connection channel that connects the control valve with the vane guide slot, a high-pressure channel that connects the control valve with a discharge side of the compressor, and a low-pressure channel that connects the control valve with an intake side of the compressor, and a throttle section that reduces the fluid channel of at least one of the high-pressure channel and the connection channel in order to reduce an initial discharge pressure applied to the vane guide slot.

Variable capacity rotary compressor having vane controller

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

A variable capacity rotary compressor to reduce an electric power loss thereof and includes a drive unit to generate a rotating force, a rotating shaft connected to the drive unit to rotate thereby, and a compressing cylinder through which the rotating shaft passes. A compressing chamber is defined in the compressing cylinder to compress refrigerant therein, with a first refrigerant inlet port provided at the compressing chamber to introduce the refrigerant into the compressing chamber. A capacity control unit controls an operation of the rotary compressor, so that the rotary compressor performs one of a normal-mode operation wherein the first refrigerant inlet port is maintained at an open state thereof, and the variable capacity-mode operation wherein the first refrigerant inlet port is periodically opened and closed.

Variable capacity rotary compressor

A variable capacity rotary compressor including first and second compression chambers having different capacities, and a rotating shaft. First and second eccentric cams are mounted to the rotating shaft to be eccentric in a same direction. First and second eccentric bushes are fitted over the first and second eccentric cams to make an angle between eccentric lines of the first and second eccentric bushes be less than 180&#xb0;. A locking pin functions to change a position of the first or second eccentric bush to a maximum eccentric position. Further, a slot is formed on the rotating shaft between the first and second eccentric bushes. In this case, the slot having a predetermined length is formed to have a same angle as the angle between the eccentric lines of the first and second eccentric bushes. The locking pin is inserted into the slot.

Growing community of inventors

Suwon-si, South Korea

Jin Kyu Choi